Denali therapeutics reports positive three-month data from phase 1/2 study with etv:ids (dnl310) in patients with hunter syndrome (mps ii)

South san francisco, calif., feb. 12, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced additional positive interim results from the ongoing phase 1/2 study evaluating etv:ids (dnl310) as a potential brain-penetrant enzyme replacement therapy for treating both central nervous system (cns) and peripheral manifestations of hunter syndrome (mps ii). the data will be presented later today during a late-breaker session at worldsymposium™. denali management will host an analyst webinar today beginning at 8:00 a.m. eastern time to discuss both interim clinical and new preclinical data that will be presented at the conference.
DNLI Ratings Summary
DNLI Quant Ranking